secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001193125-23-256533
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte subsidiary signs commercial manufacturing deal with Lonza for pneumococcal vaccine
--------------------------------------------------------------------------------

- Lonza will build a dedicated suite in Visp, Switzerland to manufacture drug substance for Vaxcyte's pneumococcal conjugate vaccine franchise.
- Vaxcyte GmbH pays CHF 27M repurposing fee within 30 days, credited over 10 years from commercial production start.
- Agreement term through Dec 31, 2038, renewable for three 5-year periods; termination penalty up to CHF 70M under certain conditions.
- Vaxcyte retains right to use alternate manufacturers; receives perpetual, royalty-free license to Lonza's IP for the Products.
- Pre-commercial service fees and capital expenditure contributions commence before suite certification for commercial operation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312523256533/0001193125-23-256533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312523256533/d572225d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-256533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer